Diasorin SpA (MIL:DIA) ROCE % : 9.65% (As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Diasorin SpA's annualized ROCE % for the quarter that ended in Jun. 2024 was 9.65%.

Diasorin SpA ROCE % Historical Data

The historical data trend for Diasorin SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA ROCE % Chart

Diasorin SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

25.80

32.04

20.99

12.03

7.75

Diasorin SpA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															8.51	7.82	8.72	9.65	8.81

Diasorin SpA ROCE % Calculation

Diasorin SpA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	230.552	/	( ( (3408.082 - 347.016)	+	(3211.439 - 320.117) )	/ 2 )
	=	230.552	/	( (3061.066	+	2891.322)	/ 2 )
	=	230.552	/	2976.194
	=	7.75 %

Diasorin SpA's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	276	/	( ( (0 - 0)	+	(3125.513 - 266.37) )	/ 1 )
	=	276	/	( ( 0	+	2859.143 )	/ 1 )
	=	276	/	2859.143
	=	9.65 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Diasorin SpA (MIL:DIA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Diasorin SpA ROCE % Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Diasorin SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (MIL:DIA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DIAm:UK 0GZX:UK 34D:Germany DIAS:Austria

Address

Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040

Website

https://www.diasoringroup.com

DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).